Susquehanna International Group’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-32,500
| Closed | -$172K | – | 14009 |
|
|
2021
Q2 | $172K | Sell |
32,500
-68,200
| -68% | -$353K | ﹤0.01% | 11751 |
|
|
2021
Q1 | $483K | Buy |
100,700
+90,500
| +887% | +$473K | ﹤0.01% | 9556 |
|
|
2020
Q4 | $44K | Buy |
+10,200
| New | +$43.6K | ﹤0.01% | 10778 |
|
|
2020
Q3 | – | Sell |
-11,400
| Closed | -$29K | – | 11416 |
|
|
2020
Q2 | $29K | Sell |
11,400
-400
| -3% | -$1.18K | ﹤0.01% | 9873 |
|
|
2020
Q1 | $34K | Sell |
11,800
-62,500
| -84% | -$280K | ﹤0.01% | 9796 |
|
|
2019
Q4 | $282K | Sell |
74,300
-12,300
| -14% | -$58.9K | ﹤0.01% | 8154 |
|
|
2019
Q3 | $443K | Buy |
86,600
+36,700
| +74% | +$227K | ﹤0.01% | 7561 |
|
|
2019
Q2 | $309K | Sell |
49,900
-45,800
| -48% | -$263K | ﹤0.01% | 8250 |
|
|
2019
Q1 | $680K | Buy |
95,700
+74,100
| +343% | +$666K | ﹤0.01% | 5723 |
|
|
2018
Q4 | $184K | Sell |
21,600
-20,500
| -49% | -$267K | ﹤0.01% | 7819 |
|
|
2018
Q3 | $843K | Sell |
42,100
-54,700
| -57% | -$1.28M | ﹤0.01% | 5562 |
|
|
2018
Q2 | $2.5M | Buy |
96,800
+19,900
| +26% | +$551K | ﹤0.01% | 3660 |
|
|
2018
Q1 | $1.84M | Buy |
76,900
+31,400
| +69% | +$990K | ﹤0.01% | 4076 |
|
|
2017
Q4 | $1.54M | Sell |
45,500
-135,300
| -75% | -$3.78M | ﹤0.01% | 4403 |
|
|
2017
Q3 | $3.83M | Buy |
180,800
+159,100
| +733% | +$2.92M | ﹤0.01% | 2872 |
|
|
2017
Q2 | $380K | Buy |
21,700
+10,800
| +99% | +$179K | ﹤0.01% | 7147 |
|
|
2017
Q1 | $191K | Buy |
+10,900
| New | +$186K | ﹤0.01% | 8041 |
|
|
2016
Q4 | – | Sell |
-20,600
| Closed | -$338K | – | 10376 |
|
|
2016
Q3 | $338K | Sell |
20,600
-1,300
| -6% | -$19.8K | ﹤0.01% | 6737 |
|
|
2016
Q2 | $332K | Buy |
+21,900
| New | +$361K | ﹤0.01% | 6789 |
|
Susquehanna International Group's ADMS Position: Q4 2021 in Review
Susquehanna International Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 38,545 shares — an estimated $189K sold.
Susquehanna International Group first reported a position in ADMS in Q4 2015 and held it in 14 quarters. The position peaked at $4.56M in Q4 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Susquehanna International Group reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Susquehanna International Group sold 38,545 Adamas Pharmaceuticals shares in Q4 2021, an estimated $189K.
- Susquehanna International Group first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 14 quarters.
- Susquehanna International Group's Adamas Pharmaceuticals position peaked at $4.56M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.